🚀Product Launch: Abiramale 250
We are proud to introduce Abiramale 250 contains Abiraterone Acetate 250 mg, an advanced androgen-biosynthesis inhibitor designed to improve outcomes in metastatic castration-resistant prostate cancer (mCRPC).
By selectively inhibiting the CYP17 enzyme, Abiramale 250 reduces androgen production from the testes, adrenal glands, and tumor tissue—helping slow disease progression and enhance patient survival.
Designed with precision manufacturing standards, Abiramale 250 ensures reliable bioavailability, consistent therapeutic performance, and dependable quality.
🔬Product Overview
Generic Name: Abiraterone Acetate
Strength: 250 mg
Formulation: Oral Tablet
Primary Indications: Abiramale 250 (Abiraterone acetate 250mg) is primarily indicated in combination with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer.
This includes patients who have:
- Progressed after androgen-deprivation therapy (ADT)
- Previously received or not received chemotherapy
Mechanism of Action: Abiramale 250 selectively inhibits CYP17 to block androgen biosynthesis, starving prostate cancer cells of the hormones they need to grow.
✅ Key Benefits
- Clinically Approved Molecule: Delivers Abiraterone Acetate as recommended for prostate cancer management.
- Improved Patient Compliance: Easy-to-administer oral tablet format.
- Quality-Assured Manufacturing: Developed under stringent quality protocols for safety and efficacy.
- Cost-Effective Therapy Option: Supports improved accessibility without compromising on standards.
- Supporting Comprehensive Care: Designed to be used alongside prednisone/prednisolone as per treatment guidelines.
👨⚕️ Target Audience
- Oncologists & Urologists seeking reliable therapy options for mCRPC patients.
- Hospitals & Cancer Care Centres focusing on evidence-based oncology treatments.
- Pharmacies & Distributors requiring consistent supply of trusted oncology formulations.
- Patients & Caregivers looking for dependable and accessible prostate cancer medications (as prescribed by physicians).
🌟 Commitment to Clinical Excellence
Abiramale 250 is built on a foundation of scientific rigor, quality assurance, and patient-centric innovation.
Our commitment includes:
- Continuous adherence to global manufacturing standards.
- Transparent quality monitoring at every stage of production.
- Support for healthcare professionals with accurate product information.
- Ensuring patient safety remains at the core of every batch released.
📦 Availability
Abiramale 250 is now available through:
- Authorized distributors and pharmacy partners
- Leading hospital pharmacies
- Oncology specialty supply chains
For bulk purchase, hospital enquiries, or distributor partnerships, contact your local representative or our customer support team.
Abiramale 250 – Elevating Standards in Prostate Cancer Care
